Skip to main content
Evidence Snapshot

Bifunctional dihydrofolate reductase-thymidylate synthase

CHEMBL2425 SINGLE PROTEIN Toxoplasma gondii
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2425
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional dihydrofolate reductase-thymidylate synthase as ChEMBL target CHEMBL2425, mapped to UniProt Q07422. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional dihydrofolate reductase-thymidylate synthase
SINGLE PROTEIN · Toxoplasma gondii
As of 2026-09-13
ChEMBL target ID
CHEMBL2425
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q07422
Bifunctional dihydrofolate reductase-thymidylate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Bifunctional dihydrofolate reductase-thymidylate synthase matters

As of 2026-09-13

Bifunctional dihydrofolate reductase-thymidylate synthase is reviewed as Bifunctional dihydrofolate reductase-thymidylate synthase (UniProt Q07422); the current evidence base includes 6 approved drugs, 791 compounds, and 134 assays, with lead potency reaching pChEMBL 9.3.

Protein context
Bifunctional dihydrofolate reductase-thymidylate synthase

Bifunctional dihydrofolate reductase-thymidylate synthase Sequence length is 610 aa.

Review this target as Bifunctional dihydrofolate reductase-thymidylate synthase, mapped to UniProt Q07422. Sequence length is 610 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q07422 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 791 compounds, and 134 assays for this target. The dominant activity type is IC50. CHEMBL190650 is the current potency anchor at pChEMBL 9.3.

Use CHEMBL190650 as the tractability anchor when discussing potency (pChEMBL 9.3).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 9.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Bifunctional dihydrofolate reductase-thymidylate synthase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q07422, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

791
Total Compounds
134
Total Assays
6
Approved Drugs
IC50: 1569.0, KI: 3.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL190650
 9.3 IC50 —
No preferred name
CHEMBL50514
 9.2 IC50 —
No preferred name
CHEMBL55063
 9.1 IC50 —
No preferred name
CHEMBL337603
 9.1 IC50 —
No preferred name
CHEMBL119
 8.9 IC50 Approved

Approved Drugs

Structure Compound First Approval
PEMETREXED
CHEMBL225072
 2004
RALTITREXED
CHEMBL225071
 1996
TRIMETREXATE
CHEMBL119
 1993
TRIMETHOPRIM
CHEMBL22
 1973
METHOTREXATE
CHEMBL34259
 1953
PYRIMETHAMINE
CHEMBL36
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2425